Patients who have a stent implanted to open a blocked coronary artery face dual risks of developing blood clots and of having ...
Three months of dual antiplatelet therapy after PCI may safely balance thrombosis and bleeding risk in both patients with low ...
The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.
BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...
WVE-N531 demonstrated statistically significant improvements in muscle biopsy measures and functional measures in patients ...
Clinical Trials Arena on MSN3d
Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular ...
Soleno Therapeutics (SLNO) “announced that the FDA has approved VYKAT XR, diazoxide choline, extended-release tablets, previously referred to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback